Core Viewpoint - The stock of Deqi Pharmaceutical-B (06996) has increased by over 14%, currently trading at 6.1 HKD with a transaction volume of 38.14 million HKD, following the announcement of six drugs, including ATG-022, being proposed for breakthrough therapy designation [1] Company Summary - ATG-022 is a self-developed Claudin 18.2 antibody-drug conjugate by Deqi Pharmaceutical [1] - Recent clinical data presented at the ASCO GI 2025 conference showed an objective response rate (ORR) of 42.9% and a disease control rate (DCR) of 95.2% in patients with high Claudin 18.2 expression (IHC 2+ ≥ 20%) [1] - For patients with low Claudin 18.2 expression (IHC 2+ < 20%), the ORR was 30.0% and the DCR was 50.0% [1] - The company plans to present the latest research data on ATG-022 at the ESMO annual meeting in October 2025 [1]
港股异动 | 德琪医药-B(06996)涨超14% Claudin 18.2 ADC拟纳入突破性疗法